Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

NCT ID: NCT00431067

Last Updated: 2014-06-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-09-30

Brief Summary

The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.

Conditions

Breast Neoplasms

Study Design

• Allocation Method: NON_RANDOMIZED
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BIBW 2992

BIBW 2992 (Afatinib) once daily until progression

Group Type: EXPERIMENTAL

BIBW 2992

Intervention Type: DRUG

Interventions

BIBW 2992

Intervention Type: DRUG

Other Intervention Names

BIBW 2992 (Afatinib) once daily until progression

Eligibility Criteria

Inclusion Criteria

1. Male or female patients with confirmed diagnosis of Stage IIIB or IV HER2-positive metastatic breast cancer(HER2 2+ and FISH positive or HER2 3+).

2. Patients must have progressed following receipt of prior standard trastuzumab treatment or standard chemotherapy in conjunction with trastuzumab. Patients with visceral disease or rapid progression should not be included if they have not had previous chemotherapy in addition to trastuzumab. Patients who are intolerant to trastuzumab and who have received adequate chemotherapy and/or hormone therapy are eligible upon progression.

3. Age 18 years or older.

4. Life expectancy of at least four (4) months.

5. Written informed consent that is consistent with ICH-GCP guidelines.

6. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance Score 0, 1 or 2.

7. Patients should not have received treatment with chemotherapy or immune therapy within the last 4 weeks (2 weeks for trastuzumab). Patients should not have received treatment with hormone therapy within the last 2 weeks.

8. Patients must have recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies to CTC less than or equal to Grade 1.

9. Patients must have recovered from previous surgery.

10. Patients must have measurable disease as defined by RECIST criteria.

Exclusion Criteria

1. Active infectious disease.

2. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.

3. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.

4. Patients with active/symptomatic brain metastases. Patients with a history of treated brain metastases must have stable or normal MRI scan at screening and be at least three months post-radiation or surgery.

5. Cardiac left ventricular function with resting ejection fraction <50%.

6. Absolute neutrophil count (ANC) less than 1500 cells/mm3.

7. Platelet count less than 100 000 cells/mm3.

8. Bilirubin greater than 1.5 mg/dl (>26 micromol /L, SI unit equivalent).

9. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal.

10. Serum creatinine greater than 1.5 mg/dl (>132 micromol/L, SI unit equivalent).

11. Women and men (and their partners) who are sexually active and unwilling to use a medically acceptable method of contraception.

12. Pregnancy or breast-feeding.

13. Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (including LHRH agonists, or other hormones taken for breast cancer), or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study. Treatment with bisphosphonates is allowed.

14. Prior treatment with an EGFR- or HER2 inhibiting drug (except trastuzumab).

15. Patients unable to comply with the protocol.

16. Active alcohol or drug abuse.

17. Patients with history of other malignancy (except for appropriately treated superficial basal cell skin cancer and surgically cured cervical cancer in situ) unless free of disease for at least 3 years.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

1200.11.3 Boehringer Ingelheim Investigational Site

Scottsdale, Arizona, United States

1200.11.7 Boehringer Ingelheim Investigational Site

Encinitas, California, United States

1200.11.4 Boehringer Ingelheim Investigational Site

Santa Monica, California, United States

1200.11.2 Boehringer Ingelheim Investigational Site

Tampa, Florida, United States

1200.11.1 Boehringer Ingelheim Investigational Site

Boston, Massachusetts, United States

1200.11.5 Boehringer Ingelheim Investigational Site

Chapel Hill, North Carolina, United States

1200.11.4401 Boehringer Ingelheim Investigational Site

Bournemouth, , United Kingdom

1200.11.4402 Boehringer Ingelheim Investigational Site

Crownhill, Plymouth, , United Kingdom

1200.11.4406 Boehringer Ingelheim Investigational Site

Guildford, , United Kingdom

1200.11.4405 Boehringer Ingelheim Investigational Site

London, , United Kingdom

1200.11.4404 Boehringer Ingelheim Investigational Site

Poole, , United Kingdom

1200.11.4403 Boehringer Ingelheim Investigational Site

Truro, , United Kingdom

Countries

United States; United Kingdom

Other Identifiers

2007-004805-80

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1200.11

Identifier Type: -

Identifier Source: org_study_id